Baishan Jiang, Ph.D

2015- Harvard Medical School/Dana-Farber Cancer Institute, Boston, MA, United States 
"Baishan Jiang"
Mean distance: (not calculated yet)
BETA: Related publications


You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Jiang B, Wang ES, Donovan KA, et al. (2019) Development of dual and selective degraders of cyclin-dependent kinases 4 and 6. Angewandte Chemie (International Ed. in English)
Brand M, Jiang B, Bauer S, et al. (2018) Homolog-Selective Degradation as a Strategy to Probe the Function of CDK6 in AML. Cell Chemical Biology
Browne CM, Jiang B, Ficarro SB, et al. (2018) A Chemoproteomic Strategy for Direct and Proteome-wide Covalent Inhibitor Target-site Identification. Journal of the American Chemical Society
Olson CM, Jiang B, Erb MA, et al. (2017) Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. Nature Chemical Biology
Huang HT, Seo HS, Zhang T, et al. (2017) MELK is not necessary for the proliferation of basal-like breast cancer cells. Elife. 6
Johannessen L, Sundberg TB, O'Connell DJ, et al. (2017) Small-molecule studies identify CDK8 as a regulator of IL-10 in myeloid cells. Nature Chemical Biology
See more...